<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30013088</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge.</ArticleTitle><Pagination><StartPage>10713</StartPage><MedlinePgn>10713</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10713</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-28281-5</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is an aetiological agent responsible for seasonal epidemics of hand-foot-and-mouth disease, which causes considerable mortality among young children. Mucosal vaccines can efficiently induce secretory IgA at mucosal surfaces and thereby prevent or limit infection at the site of virus entry. CpG oligodeoxynucleotides (ODNs), which resemble bacterial DNA, can induce the innate immune response through activation of Toll-like receptor 9. Here, we used CpG ODNs as adjuvants to investigate an EV71 mucosal vaccine in mice. In the EV71&#x2009;+&#x2009;CpG group, the EV71-specific IgG and IgA titres in the serum, nasal wash, bronchoalveolar lavage fluid, and faeces were substantially higher than those in the EV71- and phosphate-buffered saline-treated groups. Moreover, the number of EV71-specific IgG- and IgA-producing cells was also higher in the EV71&#x2009;+&#x2009;CpG group. Furthermore, T-cell proliferative responses and interleukin-17 secretion were markedly increased when CpG-adjuvanted EV71 was delivered intranasally. More importantly, the induced antibodies neutralised infection by EV71 of the C2 genotype and crossneutralised infection by EV71 of the B4 and B5 genotypes. Lastly, human scavenger receptor class B, member 2-transgenic mice intranasally immunised with the CpG-adjuvanted EV71 vaccine resisted a subsequent lethal challenge with EV71, indicating that CpG was an effective intranasal adjuvant for EV71 mucosal-vaccine development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Li-Min</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-9291-260X</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Szu-Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Pei-Yun</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Kai-Chieh</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Bor-Luen</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan. gicmbor@ntu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. gicmbor@ntu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C408982">CPG-oligonucleotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051907">Lysosomal Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009838">Oligodeoxyribonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051116">Receptors, Scavenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074299">SCARB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001992" MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051907" MajorTopicYN="N">Lysosomal Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009838" MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051116" MajorTopicYN="N">Receptors, Scavenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30013088</ArticleId><ArticleId IdType="pmc">PMC6048030</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-28281-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-018-28281-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002;26:91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP, Jr., Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J. Virol. 1999;73:9969&#x2013;9975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;39:195&#x2013;205. doi: 10.1016/0168-1702(95)00087-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J. Virol. 2010;84:3339&#x2013;3350. doi: 10.1128/JVI.01019-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01019-09</ArticleId><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg. Infect. Dis. 2003;9:461&#x2013;468. doi: 10.3201/eid0904.020395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0904.020395</ArticleId><ArticleId IdType="pmc">PMC2957976</ArticleId><ArticleId IdType="pubmed">12702227</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol. 2008;7:868&#x2013;869. doi: 10.1016/S1474-4422(08)70207-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70207-2</ArticleId><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KY. Enterovirus 71 infection and neurological complications. Korean J. Pediatr. 2016;59:395&#x2013;401. doi: 10.3345/kjp.2016.59.10.395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/kjp.2016.59.10.395</ArticleId><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY. Enterovirus 71 infection and vaccines. Clin. Exp. Vaccine Res. 2017;6:4&#x2013;14. doi: 10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895&#x2013;904. doi: 10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HL, et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine. 2008;26:2882&#x2013;2889. doi: 10.1016/j.vaccine.2008.03.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.03.041</ArticleId><ArticleId IdType="pubmed">18450335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HF, Chang MH, Chiang BL, Jeng ST. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;24:2944&#x2013;2951. doi: 10.1016/j.vaccine.2005.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.047</ArticleId><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev. Vaccines. 2016;15:803&#x2013;813. doi: 10.1080/14760584.2016.1191357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2016.1191357</ArticleId><ArticleId IdType="pubmed">27206811</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyaka PN. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol. 2017;199:9&#x2013;16. doi: 10.4049/jimmunol.1601775.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601775</ArticleId><ArticleId IdType="pmc">PMC5719502</ArticleId><ArticleId IdType="pubmed">28630108</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner R, Jensen-Jarolim E, Pali-Sch&#xf6;ll I. The ABC of clinical and experimental adjuvants&#x2014;A brief overview. Immunol. Lett. 2010;128:29&#x2013;35. doi: 10.1016/j.imlet.2009.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2009.10.005</ArticleId><ArticleId IdType="pmc">PMC2999744</ArticleId><ArticleId IdType="pubmed">19895847</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya M, et al. B cells produce type 1 IFNs in response to the TLR9 agonist CpG-A conjugated to cationic lipids. J. Immunol. 2017;199:931&#x2013;940. doi: 10.4049/jimmunol.1700348.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700348</ArticleId><ArticleId IdType="pmc">PMC5531204</ArticleId><ArticleId IdType="pubmed">28652397</ArticleId></ArticleIdList></Reference><Reference><Citation>Iho S, Maeyama J, Suzuki F. CpG oligodeoxynucleotides as mucosal adjuvants. Hum. Vaccin. Immunother. 2015;11:755&#x2013;760. doi: 10.1080/21645515.2014.1004033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2014.1004033</ArticleId><ArticleId IdType="pmc">PMC4514178</ArticleId><ArticleId IdType="pubmed">25751765</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie BS, et al. Nucleic acid vaccines: tasks and tactics. Immunol. Res. 2001;24:225&#x2013;244. doi: 10.1385/IR:24:3:225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/IR:24:3:225</ArticleId><ArticleId IdType="pubmed">11817323</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng W, Yamazaki T, Nishida Y, Hanagata N. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. BMC Biotechnol. 2011;11:88. doi: 10.1186/1472-6750-11-88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6750-11-88</ArticleId><ArticleId IdType="pmc">PMC3189879</ArticleId><ArticleId IdType="pubmed">21943407</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurk M, et al. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 2004;209:141&#x2013;154. doi: 10.1016/j.imbio.2004.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2004.02.006</ArticleId><ArticleId IdType="pubmed">15481148</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel K, et al. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin. Diagn. Lab. Immunol. 2005;12:606&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1112080</ArticleId><ArticleId IdType="pubmed">15879022</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollmer J, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004;34:251&#x2013;262. doi: 10.1002/eji.200324032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200324032</ArticleId><ArticleId IdType="pubmed">14971051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One. 2013;8:e57591. doi: 10.1371/journal.pone.0057591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 2009;183:6883&#x2013;6892. doi: 10.4049/jimmunol.0901466.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901466</ArticleId><ArticleId IdType="pubmed">19923474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 1987;7:265&#x2013;276. doi: 10.1007/BF00915547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00915547</ArticleId><ArticleId IdType="pubmed">3301884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Wang J, Zganiacz A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 2004;72:238&#x2013;246. doi: 10.1128/IAI.72.1.238-246.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.1.238-246.2004</ArticleId><ArticleId IdType="pmc">PMC344011</ArticleId><ArticleId IdType="pubmed">14688101</ArticleId></ArticleIdList></Reference><Reference><Citation>Goonetilleke NP, et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 2003;171:1602&#x2013;1609. doi: 10.4049/jimmunol.171.3.1602.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.3.1602</ArticleId><ArticleId IdType="pubmed">12874255</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 2006;6:148&#x2013;158. doi: 10.1038/nri1777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1777</ArticleId><ArticleId IdType="pubmed">16491139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, et al. A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice. Vaccine. 2017;35:4983&#x2013;4989. doi: 10.1016/j.vaccine.2017.07.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.07.073</ArticleId><ArticleId IdType="pmc">PMC5572488</ArticleId><ArticleId IdType="pubmed">28774560</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PC, Chen SC, Chen KT. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int. J. Environ. Res. Public Health. 2016;13:890. doi: 10.3390/ijerph13090890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph13090890</ArticleId><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30:1305&#x2013;1312. doi: 10.1016/j.vaccine.2011.12.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyaka PN, et al. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 2003;170:5636&#x2013;5643. doi: 10.4049/jimmunol.170.11.5636.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.11.5636</ArticleId><ArticleId IdType="pubmed">12759444</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 1998;16:1216&#x2013;1224. doi: 10.1016/S0264-410X(98)80122-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(98)80122-9</ArticleId><ArticleId IdType="pubmed">9682382</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 2004;4:249&#x2013;258. doi: 10.1038/nri1329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1329</ArticleId><ArticleId IdType="pubmed">15057783</ArticleId></ArticleIdList></Reference><Reference><Citation>Tengroth L, et al. Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells. PLoS One. 2014;9:e98239. doi: 10.1371/journal.pone.0098239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098239</ArticleId><ArticleId IdType="pmc">PMC4041746</ArticleId><ArticleId IdType="pubmed">24886842</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin T, et al. CpG oligodeoxynucleotides facilitate delivery of whole inactivated H9N2 influenza virus via transepithelial dendrites of dendritic cells in nasal mucosa. J. Virol. 2015;89:5904&#x2013;5918. doi: 10.1128/JVI.00296-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00296-15</ArticleId><ArticleId IdType="pmc">PMC4442437</ArticleId><ArticleId IdType="pubmed">25810544</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, et al. SCARB2/LIMP-2 regulates IFN production of plasmacytoid dendritic cells by mediating endosomal translocation of TLR9 and nuclear translocation of IRF7. J. Immunol. 2015;194:4737&#x2013;4749. doi: 10.4049/jimmunol.1402312.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1402312</ArticleId><ArticleId IdType="pmc">PMC4506778</ArticleId><ArticleId IdType="pubmed">25862818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Fujii K, Koike S. Receptors for enterovirus 71. Emerg. Microbes Infect. 2014;3:e53. doi: 10.1038/emi.2014.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.49</ArticleId><ArticleId IdType="pmc">PMC4126179</ArticleId><ArticleId IdType="pubmed">26038749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HW, et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One. 2013;8:e69858. doi: 10.1371/journal.pone.0069858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0069858</ArticleId><ArticleId IdType="pmc">PMC3728341</ArticleId><ArticleId IdType="pubmed">23936115</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lian WC, Butler M, Wu SC. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine. 2007;25:19&#x2013;24. doi: 10.1016/j.vaccine.2006.06.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.06.083</ArticleId><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>